1. New Agents, New Regimens, New Strategies

4. HCV Infection and Kidney Disease

5. Treating HCV Infection in Patients With CKD What Are the Current Options?

6. RUBY-1: 3D Regimen Efficacy: 100%

7. RUBY-1 Safety

8. C-SURFER Grazoprevir/Elbasvir

9. C-SURFER Grazoprevir/Elbasvir

10. Back to the Debate Treating Patients With HCV Infection and CKD and Awaiting Kidney Transplantation

11. Treating HCV Infection in Patients With Advanced Liver Disease

12. Treating HCV Infection in Patients With ESLD Awaiting Liver Transplantation

13. SOLAR-1 and SOLAR-2

14. ALLY-1

15. ALLY-1: SVR12 By Child-Pugh Class Advanced Cirrhosis Cohort, All Genotypes

16. C-SALT Grazoprevir/Elbasvir

17. IMPACT Interim Analysis, Ongoing

18. Treating HCV Infection in Patients With Decompensated Cirrhosis

19. Treating HCV Infection In Patients Who Failed to Respond to Prior Treatment

20. OPTIMIST-1 and OPTIMIST-2 Cirrhosis + RAV = Worse Outcomes

21. NS5A RAVs in Patients With Compensated Cirrhosis Who Were Treated With Ledipasvir/Sofosbuvir in Phase 2 and Phase 3 Studies* (N = 511)

22. Development of RAVs After Treatment With All-Oral Therapies

23. Retreatment for Relapse After 8 or 12 Weeks of Ledipasvir/Sofosbuvir  Ribavirin

24. C-SALVAGE Phase 2 Study of Retreatment With Grazoprevir/ Elbasvir + Ribavirin for 12 wk After Failure to Respond to a PI-based Regimen (N = 79)

25. Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir

26. Abbreviations

27. Abbreviations (cont)

28. References

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)